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HIV: The deadly passenger in dendritic cells
Sarah L. Rowland-Jones
A picture is emerging of how HIV subverts a normal
immunological surveillance mechanism to establish
primary infection. This involves the infection of dendritic
cells at mucosal surfaces: as these cells then mature,
they transport the virus to lymphoid tissue, where viral
replication begins and infection of CD4+ T cells occurs. 
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The disturbing figures released by the United Nations
Programme on AIDS at the end of last year revealed that
more than 33 million people worldwide are now infected
with human immunodeficiency virus (HIV). The vast
majority of HIV transmissions take place across a mucous
membrane, yet the very earliest events of HIV infection —
despite their obvious importance for preventative and
therapeutic strategies — remain obscure. Recent work
from a number of groups, however, has demonstrated how
a key immunological surveillance mechanism can be sub-
verted by HIV, allowing the virus to gain access to its main
target cell population, the CD4+ T cell. The dendritic cell
is the central component in this process.
Dendritic cells are now understood to provide a highly
specialised mechanism whereby an antigen encountered
in peripheral tissues, notably skin and mucosal mem-
branes, can be brought together with the T cells that will
constitute the immune response against it. It has been
pointed out that the immune system needs to have some
way of coordinating a successful T-cell response in the
face of problems posed by the scarcity of T cells with an
appropriate antigenic specificity amongst the abundance
of available lymphocytes, and the relatively low avidity of
any interaction between antigen and a low-affinity T-cell
receptor expressed by a quiescent cell lacking the critical
costimulatory molecules required to trigger a full T-cell
response [1]. The problem is more than just finding a
needle in a haystack: here, the needle is not only hard to
find, it is also blunt. Dendritic cells deal with this situation
in a remarkable way, and the key to understanding their
role has been the appreciation that the functions of these
cells change as they mature [2].
The principal form of dendritic cell in the tissues, exem-
plified by Langerhans cells in epithelial and mucosal sur-
faces, is specialised for antigen capture. These cells, also
referred to as immature or ‘processing’ dendritic cells,
have developed and refined the ability to acquire foreign
proteins by phagocytosis or pinocytosis and reduce them
to an array of antigens ready for presentation on the cell
surface [2]. These immature cells express chemokine
receptors, principally CCR5 and CCR6, which act to alert
and direct the cells to a site of inflammation where the
chemokine ligands MIP-1α, MIP-1β, RANTES and
MIP-3α are being produced [3]. Once loaded with
antigen, the dendritic cells then take the back route to the
lymph node via the draining lymphatic system. As the
cells travel, they also mature and alter their profile of cell-
surface molecules, so the dendritic cells that arrive in the
lymph node now express a range of costimulatory mole-
cules designed to attract and trigger the appropriate T
cells to respond to the antigen load that they are present-
ing. The principal chemokine receptor expressed by
mature or ‘presenting’ dendritic cells is CCR7, the ligand
for which, MIP-3β, is produced in the T-cell-rich areas of
lymphoid tissue, thus drawing the dendritic cells towards
the T cells [3]. One of the central interactions that now
takes place is between the CD40 ligand (CD40L)
expressed on the surface of T cells and CD40 on mature
dendritic cells: this appears to be critical for the survival,
maturation and cytokine production of the dendritic cells,
whilst at the same time facilitating the antigen-specific
priming of the T cells [4].
Mature dendritic cells are believed to be the most potent
stimulators of CD4+ helper T lymphocyte and CD8+ cyto-
toxic T lymphocyte (CTL) responses in the immune
system [5]. Recent studies have shown that a dendritic
cell activated by CD40 triggering can serve to bridge the
gap between the help supplied by responding CD4+ T
cells and that needed to stimulate specific CTLs, without
necessarily requiring all the players to be in the same
place at the same time [6]. The authors speculate that the
direct infection of dendritic cells could directly empower
them to stimulate CTLs and bypass the need for CD4+
help: a prediction from this model is that the ability of a
pathogen to infect and activate dendritic cells would cor-
relate with the independence of specific CTLs from
CD4+ T-cell help [6].
How has HIV taken advantage of this highly sophisticated
system to establish a persistent infection of CD4+ T cells?
Increasingly, a consensus has emerged that dendritic cells
are likely to be the first cells targeted by HIV in the
mucosa [7]. But although the early controversy of whether
dendritic cells were directly infected with HIV or simply
carrying the virus on their surface has largely been
resolved in favour of the former [7], the role of dendritic
cells in disseminating the virus to T cells has not been
clear. A recent paper by Granelli-Piperno and colleagues
[8] puts some missing pieces into the picture that is
emerging from a number of studies. This group had previ-
ously shown that HIV could enter immature dendritic
cells but that replication was incomplete, with only very
early HIV transcripts being produced [9]. In the presence
of T cells, however, the virus in mature dendritic cells is
triggered to set up a vigorous and productive infection
which is rapidly transmitted to the T cells. 
By using artificial constructs of HIV that can readily enter
cells but are unable to carry out further replication, the
authors show that only the first round of HIV replication
takes place in the dendritic cells and that all the subse-
quent viral replication occurs in the T cells [8]. Earlier
suggestions that the CD40–CD40L interaction plays a
crucial part in triggering replication [7] were confirmed by
incubating purified mature dendritic cells with CD40L-
transfected fibroblasts: this stimulated HIV replication in
the dendritic cells [8]. It now looks as though HIV gains
access to the lymphoid system by infecting the dendritic
cells that guard mucosal and epithelial surfaces, and then
hitching a ride to the nearest lymphoid tissue in a state of
arrested replication. The increase in mucosal dendritic cell
numbers at sites of inflammation probably contributes to
the increased risk of HIV transmission in the presence of
genital infections. Upon reaching the lymphoid regions,
the now mature dendritic cells attract and are attracted by
CD4+ T cells, which, in the course of their normal positive
feedback interaction with the dendritic cells through their
costimulatory molecules, can release the block to the virus
life cycle and allow new HIV particles to be rapidly made
(Figure 1). The emerging virions now have access to a
wealth of activated T cells in the vicinity, so can leave the
shelter of the dendritic cells for a more permissive host.
A number of questions still remain. It seems likely that the
use of dendritic cells for initial HIV entry imposes the
selection for viral strains that use the CCR5 receptor
expressed on immature dendritic cells in order to establish
primary infection. But although immature dendritic cells
may still express a certain amount of CXCR4, there seems
to be a barrier to the entry of the later, more aggressive
viral strains that use this receptor, and this has yet to be
fully explained. The mechanism by which virus replica-
tion is arrested until the first contact is established
between T cells and dendritic cells is not at all understood.
The fate of the carrier dendritic cells once they have
handed on their passengers to the T cells is also not clear.
There is some suggestion that these dendritic cells may
die through apoptosis or following recognition by CTLs
[5], but it is also plausible that many survive and continue
their mission to stimulate HIV-specific responses. 
Is the function of the carrier dendritic cells compromised
by HIV infection? Studies on dendritic cells derived from
the blood of patients at later stages of HIV infection
suggest that there is a generalised defect in antigen-
presenting function, which may underlie the ultimate
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A scheme to show how HIV uses the dendritic cell (DC) to gain access to T cells in the lymph node. HIV infects immature dendritic cells after
penetrating the mucosa but only the very early stages of replication are carried out in these cells. The maturing dendritic cells transport virus to the
lymphoid tissue where virus replication is triggered by interaction with T cells, which may then be infected by the emerging virus.
failure of the immune response to control the virus [5].
Primary infection with HIV often provokes an early and
vigorous CTL response, however, in which the infected
dendritic cells are very probably playing a part. Indeed, the
proposed ability of infected dendritic cells to bypass the
requirement for CD4+ T-cell help [6] could explain how
such a strong CTL response can be initiated and main-
tained for so long in the apparent absence of HIV-specific
helper responses in most infected people. Increasing
evidence suggests, however, that CTLs are functionally
deficient without the support of CD4+ T-cell help [10].
The implications of early dendritic cell infection for the
successful generation of HIV-specific immunity therefore
need to be unravelled.
Are there stages in the passage of HIV from mucosa to
lymph node that provide targets for therapeutic interven-
tion? The apparent requirement for HIV to use CCR5 to
establish primary infection has already led to considerable
efforts to identify agents that will block this receptor.
Once the dendritic cells have been infected, it is possible
that drugs such as steroids may prevent their maturation
and migration to the lymph nodes [8]. The recent study
by Granelli-Piperno and colleagues [8] also suggests that
strategies to disrupt the CD40–CD40L interaction could
be potentially useful. Finally, the reported resistance of
the virus sequestered in dendritic cells to the activity of
the anti-HIV drug azidothymidine (AZT) [8] raises the
question of how the spread of HIV infection could be con-
trolled by therapy after the initial exposure: perhaps den-
dritic cells do become infected but are prevented from
passing on the virus to T cells. These cells could still stim-
ulate an effective immune response. HIV-specific cellular
immune responses can be demonstrated in a surprising
number of people with HIV exposure who remain
seronegative [11]: this may reflect a low-level infection
confined to a few dendritic cells that are still able to
trigger CTLs and CD4+ responses. 
Despite the questions that remain, it is clear that improv-
ing our understanding of how HIV breaks into the body
by subverting some of our best defence mechanisms must
give us a better opportunity to turn the tables in our
favour in the future.
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